NAD+

The short version

Why people discuss it

AxonRep’s community research identifies recurring interest in NAD+ for longevity, cellular energy and metabolic health. Human studies often evaluate NADH or NAD+ precursors instead, so those results cannot be assigned wholesale to intravenous or oral NAD+.

What it is

NAD+ is an essential cellular coenzyme, not a peptide. NAD+, NADH, nicotinamide riboside and nicotinamide mononucleotide are distinct substances and routes with different evidence.

Biggest caution

FDA has received adverse-event reports after injectable NAD+ products, including severe chills, shaking, vomiting and fatigue, in a contamination context involving unsuitable food-grade ingredients. Route and ingredient quality are central to interpreting risk.

Stack context

Community mitochondrial discussions often group NAD+ with MOTS-c and SS-31. Repeated pairing does not establish combined benefit, compatible dosing or safety.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.